Displaying drugs 15051 - 15075 of 15130 in total
AP5280
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Investigational
MAS825
Investigational
INS 316
INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer. It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.
Investigational
5-Amidino-Benzimidazole
Experimental
R-348
Investigational
Bis(5-Amidino-Benzimidazolyl)Methane
Experimental
Mebicar
Experimental
ALKS 27
ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD). Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.
Investigational
Ezurpimtrostat
Investigational
Hemi-Babim
Experimental
KB002
KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.
Investigational
Benzo[B]Thiophene-2-Carboxamidine
Experimental
Bioymifi
Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053]
Investigational
6-Hydroxy-5-undecyl-4,7-benzothiazoledione
Experimental
Flaviolin
Experimental
Dihydroquinidine barbiturate
Experimental
ING-1
ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractive target for immunotherapy.
Investigational
R450
R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence. Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.
Investigational
RG-7795
Investigational
Quinalizarin
Experimental
Ganglioside GM1
Investigational
Matched Iupac: … hydroxymethyl)oxan-4-yl]oxy}-5-acetamido-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid …
Plinabulin
Investigational
CRA_1801
Experimental
Displaying drugs 15051 - 15075 of 15130 in total